Albireo Pharma Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $915.89 million
- Book Value:
- Revenue TTM:
- $57.39 million
- Operating Margin TTM:
- Gross Profit TTM:
- $39.22 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Albireo Pharma Inc had its IPO on 2007-05-11 under the ticker symbol ALBO.
The company operates in the Healthcare sector and Biotechnology industry. Albireo Pharma Inc has a staff strength of 130 employees.
Shares of Albireo Pharma Inc opened at $44.9 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $43.99 - $44.9, and closed at $44.15.
This is a -0.23% slip from the previous day's closing price.
A total volume of 1,260,806 shares were traded at the close of the day’s session.
In the last one week, shares of Albireo Pharma Inc have increased by +1.49%.
Albireo Pharma Inc's Key Ratios
Albireo Pharma Inc has a market cap of $915.89 million, indicating a price to book ratio of 4.3049 and a price to sales ratio of 7.3476.
In the last 12-months Albireo Pharma Inc’s revenue was $57.39 million with a gross profit of $39.22 million and an EBITDA of $-122812000. The EBITDA ratio measures Albireo Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Albireo Pharma Inc’s operating margin was -214.74% while its return on assets stood at -24.94% with a return of equity of -93.08%.
In Q3, Albireo Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 168.3%.
Albireo Pharma Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-6.66 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Albireo Pharma Inc’s profitability.
Albireo Pharma Inc stock is trading at a EV to sales ratio of 4.53 and a EV to EBITDA ratio of -2.112. Its price to sales ratio in the trailing 12-months stood at 7.3476.
Albireo Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $321.22 million
- Total Liabilities
- $37.82 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Albireo Pharma Inc ended 2023 with $321.22 million in total assets and $0 in total liabilities. Its intangible assets were valued at $321.22 million while shareholder equity stood at $100.07 million.
Albireo Pharma Inc ended 2023 with $0 in deferred long-term liabilities, $37.82 million in other current liabilities, 207000.00 in common stock, $-421033000.00 in retained earnings and $17.26 million in goodwill. Its cash balance stood at $222.48 million and cash and short-term investments were $222.48 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Albireo Pharma Inc’s total current assets stands at $238.84 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.03 million compared to accounts payable of $6.95 million and inventory worth $3.15 million.
In 2023, Albireo Pharma Inc's operating cash flow was $-40000.00 while its capital expenditure stood at $960000.
Comparatively, Albireo Pharma Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Albireo Pharma Inc stock is currently trading at $44.15 per share. It touched a 52-week high of $45.23 and a 52-week low of $45.23. Analysts tracking the stock have a 12-month average target price of $43.8.
Its 50-day moving average was $37.97 and 200-day moving average was $25.15 The short ratio stood at 1.38 indicating a short percent outstanding of 0%.
Around 361% of the company’s stock are held by insiders while 10768.9% are held by institutions.
Frequently Asked Questions About Albireo Pharma Inc
Similar Industry Stocks (Biotechnology)
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. As of March 1, 2023, Albireo Pharma, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..